A recent study demonstrated in the ex-vivo setting the impact of transforming growth factor beta 1 (TGF-β1), which induced NK-cell dysfunction in AML patients with early relapse after allo-HCT. This evidence concerns the gene TGFB1 and acute myeloid leukemia.